A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia

ClinicalTrials.gov Identifier: NCT02660112
Sponsor: Ralitza Gavrilova
Collaborator: Cardero Therapeutics, Inc.
Information provided by (Responsible Party): Ralitza Gavrilova, Mayo Clinic
First received: January 18, 2016

This 24-week study will test the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have Friedreich's Ataxia, a neurological disorder.


A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia